The aim of this study was to evaluate serum and synovial levels of IL-17A by ELISA in rheumatoid arthritis (RA) and find out the correlations between IL-17A levels and various clinical, laboratory parameters and RA disease activity and severity indices. Group I consists of 30 adult active RA patients fulfilling the ARA 1987 revised criteria, with knee effusion and receiving basic therapy, and with a mean age of 41.47±11.49 years and mean disease duration of 9.5±4.16 years. Group II consisted of 13 healthy volunteers, age- and sex-matched, with a mean age of 39.08±14.19 years. RA patients showed significantly higher mean serum IL-17A levels than controls (11.25±9.67 vs. 0.6±1.4 pg/mL, respectively, p=0.0002). Synovial IL-17A levels showed a significant positive correlation with serum IL-17A levels (r=0.5 and p=0.005). RA patients with negative rheumatoid factor (RF) had non-significantly higher mean serum IL-17A levels (12±9.86 pg/mL) compared to those with positive RF (10.82±9.81 pg/mL); however, the mean synovial IL-17A levels were nearly the same. Significant positive correlations were found between both serum and synovial IL-17A levels and DAS-28 scores (r=0.556, 0.392 and p=0.001, 0.032, respectively). RA patients with class III functional status showed significantly higher mean serum IL-17A levels (17.53±13.43 pg/mL) than classes I and II (8.97±6.97 pg/mL, p=0.009). These led us to conclude that the elevated serum and synovial IL-17A levels in RA patients parallel the degree of disease activity and severity. This may highlight the usefulness of IL-17 (especially serum level) as a possible marker for more aggressive joint involvement and damage.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.